Freedom Capital lowered shares of AtriCure (NASDAQ:ATRC – Free Report) from a strong-buy rating to a hold rating in a research note issued to investors on Friday,Zacks reports.
Several other research firms also recently commented on ATRC. Needham & Company LLC lifted their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. UBS Group decreased their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. BTIG Research upped their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Finally, Piper Sandler boosted their target price on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.30.
Check Out Our Latest Stock Analysis on ATRC
AtriCure Stock Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure will post 0.29 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the sale, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 74,868 shares of company stock worth $3,317,897 over the last quarter. Company insiders own 4.00% of the company’s stock.
Hedge Funds Weigh In On AtriCure
Several large investors have recently made changes to their positions in ATRC. Tidal Investments LLC raised its stake in AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after buying an additional 6,034 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of AtriCure in the second quarter worth approximately $1,002,000. Engineers Gate Manager LP lifted its stake in shares of AtriCure by 12.3% in the second quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock worth $1,348,000 after buying an additional 5,283 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of AtriCure during the second quarter valued at approximately $46,000. Finally, Allworth Financial LP increased its position in shares of AtriCure by 372.8% during the second quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 1,204 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.
About AtriCure
AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.
The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.
See Also
- Five stocks we like better than AtriCure
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
